Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032
Overview
The Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 is expected to reach a 238.84 USD Million by 2032 and is projected to grow at a CAGR of 20.40% from 2025 to 2032.
Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 2018-2032 USD Million
Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 79.28 USD Million
- Projected Market Size (2032): 238.84 USD Million
- CAGR (2025-2032): 20.40%
Key Findings of Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030
- The Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 was valued at 79.28 USD Million in 2024.
- The Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 is likely to grow at a CAGR of 20.40% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Parenteral in Route of Administration Segment accounted for the largest share of the market with a revenue of 63.48 USD Million
- The fastest growing segment Steroid Therapy in Treatment Segment grew Fastest with a CAGR of 21.17% during the forecast period from 2024 to 2032.
Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 Scope
- Others
- Steroid Therapy
- Molecular-Based Therapies
- Dystrophin-Targeted Therapies
- Mutation Suppression
- Exon Skipping Approach
- Others
- Oral
- Parenteral
- Others
- Homecare
- Specialty Clinics
- Hospitals
- Online Pharmacy
- Retail Pharmacy
- Hospital Pharmacy
Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 79.28 USD Million |
| Market Value in 2032 | 238.84 USD Million |
| CAGR (2025-2032) | 20.40% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Treatment,Therapy,Route of Administration ,End User,Distribution Channel |
Regional Insights:
-
Leading Market (2024-2032): Middle East & Africa, leading in terms of revenue 79.28 USD Million in 2024
- Key Country: South Africa, leading in terms of revenue with value of 33.21 USD Million in 2024.
Segments and Scope
-
Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032, By Treatment
- Molecular-Based Therapies is the largest segment in Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032 with a revenue of 41.82 USD Million in the year 2024.
- Steroid Therapy is the Fastest growing segment in Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032 with a Growth rate of 20.17 % in forecast period 2025-2032.
-
Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032, By Therapy
- Exon Skipping Approach is the largest segment in Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032 with a revenue of 52.13 USD Million in the year 2024.
- Exon Skipping Approach is the Fastest growing segment in Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032 with a Growth rate of 20.67 % in forecast period 2025-2032.
-
Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032, By Route of Administration
- Parenteral is the largest segment in Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032 with a revenue of 63.48 USD Million in the year 2024.
- Parenteral is the Fastest growing segment in Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032 with a Growth rate of 20.85 % in forecast period 2025-2032.
-
Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032, By End User
- Hospitals is the largest segment in Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032 with a revenue of 52.21 USD Million in the year 2024.
- Hospitals is the Fastest growing segment in Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032 with a Growth rate of 20.69 % in forecast period 2025-2032.
-
Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032, By Distribution Channel
- Hospital Pharmacy is the largest segment in Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032 with a revenue of 56.14 USD Million in the year 2024.
- Hospital Pharmacy is the Fastest growing segment in Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 to 2032 with a Growth rate of 20.74 % in forecast period 2025-2032.
Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 Company Share Analysis
| Company Name |
|
||
| Pfizer Inc. | |||
| F. Hoffmann-La Roche Ltd. | |||
| PTC Therapeutics. | |||
| Sarepta Therapeutics, Inc. | |||
Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 Geographical Sales Distribution, 2018-2032 USD Million
Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 Company Profiling
Industry Related Reports
Frequently Asked Questions
Coming Soon....
Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 Scope
- Others
- Steroid Therapy
- Molecular-Based Therapies
- Dystrophin-Targeted Therapies
- Mutation Suppression
- Exon Skipping Approach
- Others
- Oral
- Parenteral
- Others
- Homecare
- Specialty Clinics
- Hospitals
- Online Pharmacy
- Retail Pharmacy
- Hospital Pharmacy
Frequently Asked Questions
Middle East & Africa Duchenne Muscular Dystrophy Treatment Market 2030 Company Profiling
Frequently Asked Questions
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.